---
document_datetime: 2024-02-29 11:16:55
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-teva-hydrogen-sulphate-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-teva-hydrogen-sulphate-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.907174
conversion_datetime: 2025-12-20 08:39:36.642513
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Clopidogrel Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0061/G            | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect | 26/02/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | - Change in immediate packaging of the product - Qualitative and quantitative - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        | B.II.e.1.a.1 finished composition   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------|
| IB/0059/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 09/01/2024 | 08/02/2024 | SmPC, Labelling and PL |                                     |
| IA/0060/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or                                                                              | 20/11/2023 | n/a        |                        | deletion of Ph.                     |

<div style=\"page-break-after: always\"></div>

|           | relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0057   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 03/06/2022 | 15/09/2023 | SmPC, Labelling and PL | Section 4.5 of the SmPC was updated to add the drug-drug interaction between clopidogrel and rosuvastatin following the same update for the reference product. The package leaflet was updated accordingly. |
| IG/1508   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                             | 23/05/2022 | n/a        |                        |                                                                                                                                                                                                             |
| IB/0056   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 04/10/2021 | 26/11/2021 | SmPC and PL            |                                                                                                                                                                                                             |
| IB/0055   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 03/05/2021 | 19/05/2021 | SmPC and PL            |                                                                                                                                                                                                             |
| IA/0054/G | This was an application for a group of variations.                                                                                                                                                                                                           | 02/03/2021 | n/a        |                        |                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|             | in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |            |                        | B.II.d.2.a - Change   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| IAIN/0053/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites                                                                                                  | 04/02/2021 | 19/05/2021 | Annex II and PL        |                       |
| IB/0052     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                         | 24/11/2020 | 19/05/2021 | SmPC, Labelling and PL |                       |
| IB/0051/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO                                                                 | 21/02/2020 | 04/05/2020 | SmPC, Annex II and PL  |                       |

<div style=\"page-break-after: always\"></div>

|           | data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                     |            |            |                        | new additional   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------|
| IAIN/0050 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/08/2019 | 04/05/2020 | SmPC and PL            |                  |
| IA/0048   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                  | 31/05/2019 | n/a        |                        |                  |
| IB/0049/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 28/05/2019 | 04/05/2020 | SmPC, Labelling and PL |                  |

<div style=\"page-break-after: always\"></div>

| IAIN/0047/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging   | 21/11/2018   | n/a        |                 | site   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|--------|
| IB/0046       | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                        | 25/09/2018   | n/a        |                 |        |
| IB/0045       | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                      | 13/04/2018   | 31/01/2019 | SmPC and PL     |        |
| IAIN/0044     | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                            | 04/12/2017   | 31/01/2019 | Annex II and PL |        |
| IA/0043/G     | This was an application for a group of variations.                                                                                                                                                                                                                                                                | 21/09/2017   | n/a        |                 |        |

<div style=\"page-break-after: always\"></div>

|           | - Change in the manufacturing process of finished or intermediate product - Minor change the manufacturing process - Change in the manufacturing process of finished or intermediate product - Minor change the manufacturing process                                                                                                                                                                                                                                                                                                                                |            |            |                        | B.II.b.3.a the in B.II.b.3.a the in   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------|
| IB/0042/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 22/05/2017 | 23/06/2017 | SmPC, Labelling and PL | the MAH                               |
| IA/0041/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.III.1.a.2 - Submission of a new/updated or Eur. Certificate of Suitability to the                                                                                                                                                                                                         | 06/03/2017 | n/a        |                        | deletion of Ph.                       |

<div style=\"page-break-after: always\"></div>

|           | relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                |            |            |                 |         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------|
| IA/0040/G | This was an application for a group of variations. B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- medicinal products | 16/12/2016 | n/a        |                 | sterile |
| IAIN/0039 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/09/2016 | 23/06/2017 | Annex II and PL |         |
| IB/0038/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                                                                                                                                                                                                                                                                                                                  | 10/12/2015 | 26/05/2016 | SmPC and PL     |         |

<div style=\"page-break-after: always\"></div>

|           | new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                     | product - Implementation   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|----------------------------|
| IAIN/0037 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                 | 27/11/2015 | 26/05/2016 | Annex II and PL     |                            |
| IB/0036   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                           | 01/06/2015 | 26/05/2016 | SmPC and PL         |                            |
| T/0034    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/01/2015 | 30/01/2015 | SmPC, Labelling and |                            |

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                 |            |            | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0035         | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                              | 21/01/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0033           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate    | 28/11/2014 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/820/2 01311 | Periodic Safety Update EU Single assessment - acetylsalicylic acid / clopidogrel, clopidogrel                                                                                                                   | 10/07/2014 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| R/0029            | Renewal of the marketing authorisation.                                                                                                                                                                         | 20/03/2014 | 16/05/2014 | SmPC, Labelling and PL | The safety and efficacy of clopidogrel have been demonstrated by several large clinical studies. The MAH has submitted an Addendum to Clinical Overview (ACO) to provide details of the efficacy and safety of Clopidogrel Teva since its approval. In the CHMP's view the provided data do not change the overall knowledge about the beneficial effect and safety profile of clopidogrel when used in the approved indications. The beneficial effect of Clopidogrel Teva remains in line with that of the originator product (Plavix), and is considered positive. |
| IB/0032/G         | This was an application for a group of variations. Following an assessment of safety updates for the reference product, the MAH applied to update section 4.4 'Special Warning and Precautions for use' and 4.5 | 23/04/2014 | 30/01/2015 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 'Interaction with other SmPC in order to add Sheets linked to clopidogrel - Addition of an interaction serotonin reuptake inhibitors - Addition of a consequential this interaction in section The Section 2 of the Package updated accordingly. To update section 4.8 Organ Class: Skin and of the SmPC to add information linked to clopidogrel INN: - Addition of a new undesirable exfoliative'. Finally, minor editorial in section 5 of labelling contact details of the local Luxembourg, Malta, Iceland updated. Also, the Danish, Package Leaflet were brought innovator text as some detected. C.I.2.a - Change in the generic/hybrid/biosimilar assessment of the same product - Implementation new additional data is   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                   |            |            |             |         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------|
| IB/0030   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                           | 10/02/2014 | 16/05/2014 | SmPC and PL | the MAH |
| IB/0028   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                         | 03/12/2013 | n/a        |             |         |
| IB/0027/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 06/11/2013 | 16/05/2014 | SmPC and PL |         |

<div style=\"page-break-after: always\"></div>

|             | additional data is required to be submitted by MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                                  | new the   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------|
| IAIN/0026/G | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 17/10/2013 | n/a        |                                  | site      |
| IB/0024/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO                                                                                                                                                 | 15/08/2013 | 16/05/2014 | SmPC, Annex II, Labelling and PL |           |

<div style=\"page-break-after: always\"></div>

|           | new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                           |            |            |                        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IAIN/0023 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                     | 14/08/2013 | 16/05/2014 | SmPC, Labelling and PL |
| IAIN/0022 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                         | 17/07/2013 | n/a        |                        |
| IB/0021   | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                              | 18/04/2013 | n/a        |                        |
| IA/0020/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites | 16/04/2013 | 16/05/2014 | Annex II and PL        |
| IB/0019   | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary                                                                                                                                                                            | 13/03/2012 | n/a        |                        |

<div style=\"page-break-after: always\"></div>

|           | for non-sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     | packaging,          |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------|
| IB/0018   | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                                                          | 16/02/2012 | n/a |                     |
| IB/0017/G | This was an application for a group of variations. B.III.2.a.1 - Change of specification('s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer A.7 - Administrative change - Deletion of | 09/01/2012 | n/a | manufacturing sites |
| IB/0016/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.c.3.b - Change in test procedure for the of the AS - Other changes to a                                                                                                                                        | 23/09/2011 | n/a | immediate packaging |

<div style=\"page-break-after: always\"></div>

|           | test procedure (including replacement or addition) B.I.c.2.c - Change in the specification parameters and/or limits of the immediate packaging of the AS - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.a.1 - Change of specification('s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                                                                                                 |            |     |                                  |                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0015/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 08/08/2011 | n/a | SmPC, Annex II and PL            |                                                                                                                                                                                                                                   |
| IB/0014   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                           | 13/07/2011 | n/a |                                  |                                                                                                                                                                                                                                   |
| IB/0013   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO                                                                                                                                                                                                                                                                                                                                                | 11/04/2011 | n/a | SmPC, Annex II, Labelling and PL | The MAH wishes to amend the SmPC and PL to put it in line with the recently adopted text of the innovator product Plavix. The sections to be updated are the following: 4.2 'Posology and method of administration', 4.4 'Special |

<div style=\"page-break-after: always\"></div>

|           | new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                   |            |     |                        | warnings and precautions for use', 4.5 'Interaction with othet medicinal products and other forms of interaction' and 5.2 'Phamakokinetics properties'. In addition the PhV system in Annex II has been amended and local representatives in Austria, Germany and Spain have been updated. Finally minor amendments have been introduced in the Annexes of the following languages: DA, NL, FI, HU, LV, LT, MT, PL, SL   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0012/G | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding | 16/11/2010 | n/a |                        |                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0011   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                 | 16/07/2010 | n/a | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0010   | To add a desiccant as an intermediate packaging component for the active substance. B.I.c.z - Container closure system of the AS - Other                                                                                                                                                                                                                                                                       | 24/06/2010 | n/a |                        |                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | variation                                                                                  |            |            |                        |
|---------|--------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IA/0009 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                   | 09/12/2009 | n/a        |                        |
| IA/0001 | IA_29_b_Change in qual./quant. composition of immediate packaging - all other pharm. forms | 30/09/2009 | n/a        | SmPC, Labelling and PL |
| IA/0008 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size    | 24/09/2009 | 24/09/2009 | SmPC, Labelling and PL |
| IA/0007 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size    | 24/09/2009 | 24/09/2009 | SmPC, Labelling and PL |
| IA/0006 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size    | 24/09/2009 | 24/09/2009 | SmPC, Labelling and PL |
| IA/0005 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size    | 24/09/2009 | 24/09/2009 | SmPC, Labelling and PL |
| IA/0004 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size    | 24/09/2009 | 24/09/2009 | SmPC, Labelling and PL |
| IA/0003 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size    | 24/09/2009 | 24/09/2009 | SmPC, Labelling and PL |
| IA/0002 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size    | 24/09/2009 | 24/09/2009 | SmPC, Labelling and    |

<div style=\"page-break-after: always\"></div>

| PL   |
|------|